Sector News

Bayer eyes new corporate structure by Jan 2016

February 13, 2015
Life sciences
(Reuters) – German healthcare group Bayer has started working on a new corporate set-up for the life-science businesses that will remain when its plastics division is split off, aiming for a new structure at the beginning of next year.
 
Employees were informed on Wednesday that a team had been set up to map out the new structure, which will not entail job cuts, a spokesman said on Thursday.
 
“We expect the number of jobs to be stable worldwide and in Germany over the next few years,” he added.
 
Bayer, whose products include cancer drugs, birth control pills, veterinary drugs, pesticides and transparent plastics, unveiled plans in September to list its plastics business on the stock market to focus on its more profitable life-science businesses.
 
It said at the time it was eyeing a spin-off or initial public offering of the MaterialScience unit within 12-18 months.
 
Its three main divisions HealthCare, CropScience and MaterialScience each have largely autonomous management teams but the company has recently stressed the synergies to be gained in the research into human, animal and plant health. (Reporting by Ludwig Burger; Editing by Mark Potter)

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).